ES2623176T3 - Composición farmacéutica de memantina - Google Patents
Composición farmacéutica de memantina Download PDFInfo
- Publication number
- ES2623176T3 ES2623176T3 ES13752800.6T ES13752800T ES2623176T3 ES 2623176 T3 ES2623176 T3 ES 2623176T3 ES 13752800 T ES13752800 T ES 13752800T ES 2623176 T3 ES2623176 T3 ES 2623176T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical form
- memantine
- solid oral
- hours
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960004640 memantine Drugs 0.000 title abstract description 14
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 11
- 150000003839 salts Chemical class 0.000 abstract description 6
- 239000007787 solid Substances 0.000 abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 16
- 238000013270 controlled release Methods 0.000 description 10
- 230000002035 prolonged effect Effects 0.000 description 7
- 230000003232 mucoadhesive effect Effects 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- -1 ethyl methyl Chemical group 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229960000967 memantine hydrochloride Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683875P | 2012-08-16 | 2012-08-16 | |
| US201261683875P | 2012-08-16 | ||
| US201361833348P | 2013-06-10 | 2013-06-10 | |
| US201361833348P | 2013-06-10 | ||
| PCT/US2013/055420 WO2014028878A1 (en) | 2012-08-16 | 2013-08-16 | Pharmaceutical compositions of memantine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2623176T3 true ES2623176T3 (es) | 2017-07-10 |
Family
ID=49029259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13752800.6T Active ES2623176T3 (es) | 2012-08-16 | 2013-08-16 | Composición farmacéutica de memantina |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20140050784A1 (enExample) |
| EP (1) | EP2884967B1 (enExample) |
| CN (1) | CN104755074A (enExample) |
| AU (1) | AU2013302359A1 (enExample) |
| ES (1) | ES2623176T3 (enExample) |
| IL (1) | IL237139A0 (enExample) |
| IN (1) | IN2015DN01023A (enExample) |
| MX (1) | MX2015001917A (enExample) |
| RU (1) | RU2015107517A (enExample) |
| WO (1) | WO2014028878A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016016406A (es) | 2014-06-11 | 2017-10-12 | Massachusetts Inst Technology | Estructuras de permanencia, y métodos relacionados. |
| US20170266112A1 (en) | 2014-06-11 | 2017-09-21 | Massachusetts Institute Of Technology | Residence structures and related methods |
| CN104586807B (zh) * | 2014-12-25 | 2018-03-30 | 广州帝奇医药技术有限公司 | 用于治疗阿尔茨海默症的缓释制剂及其制备方法 |
| AU2016342374B2 (en) | 2015-10-23 | 2022-08-04 | Nortiva Bio, Inc. | Gastric residence systems for sustained release of therapeutic agents and methods of use thereof |
| KR102796240B1 (ko) | 2015-12-08 | 2025-04-16 | 린드라 테라퓨틱스 인코퍼레이티드 | 위 체류 시스템을 위한 기하 구성형태 |
| US12109305B2 (en) | 2016-05-27 | 2024-10-08 | Lyndra Therapeutics, Inc. | Materials architecture for gastric residence systems |
| EP3518902A4 (en) * | 2016-09-30 | 2020-07-08 | Lyndra, Inc. | GASTRIC RESIDENCE SYSTEMS FOR LONG-TERM ADMINISTRATION OF ADAMANTANE CLASS MEDICINES |
| CN107213130B (zh) * | 2017-05-12 | 2018-05-11 | 上海奥科达生物医药科技有限公司 | 一种恩替卡韦药用组合物、制备方法及其应用 |
| TWI811221B (zh) | 2017-06-09 | 2023-08-11 | 美商萊恩卓治療公司 | 具有釋放速率調節膜之胃的滯留系統 |
| US11413302B2 (en) * | 2018-01-19 | 2022-08-16 | Shenyang Fuyang Pharmaceutical Technology Co., Ltd. | Use of carrimycin or active ingredients thereof and use thereof |
| EP4190319A4 (en) * | 2020-07-29 | 2024-05-01 | Novamedica Limited Liability Company | Pharmaceutical composition comprising memantine and citicoline |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| US20060002999A1 (en) | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| WO2006009769A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
| US20080279819A1 (en) * | 2005-02-15 | 2008-11-13 | Adamas Pharmaceuticals, Inc. | Combinations Therapy for Treatment of Demyelinating Conditions |
| EA013474B1 (ru) | 2005-06-16 | 2010-04-30 | Форест Лэборэтериз, Инк. | Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина |
| TWI491395B (zh) * | 2009-09-30 | 2015-07-11 | Ct Lab Inc | 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方 |
| US20140004189A1 (en) * | 2011-01-25 | 2014-01-02 | Cadila Healthcare Limited | Modified release pharmaceutical compositions memantine |
| TR201104108A2 (tr) * | 2011-04-27 | 2011-08-22 | Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. | Uzatılmış salımlı memantin tablet. |
-
2013
- 2013-08-16 ES ES13752800.6T patent/ES2623176T3/es active Active
- 2013-08-16 MX MX2015001917A patent/MX2015001917A/es unknown
- 2013-08-16 CN CN201380054072.8A patent/CN104755074A/zh active Pending
- 2013-08-16 AU AU2013302359A patent/AU2013302359A1/en not_active Abandoned
- 2013-08-16 WO PCT/US2013/055420 patent/WO2014028878A1/en not_active Ceased
- 2013-08-16 EP EP13752800.6A patent/EP2884967B1/en not_active Not-in-force
- 2013-08-16 RU RU2015107517A patent/RU2015107517A/ru not_active Application Discontinuation
- 2013-08-16 US US13/969,161 patent/US20140050784A1/en not_active Abandoned
- 2013-08-16 IN IN1023DEN2015 patent/IN2015DN01023A/en unknown
-
2015
- 2015-02-08 IL IL237139A patent/IL237139A0/en unknown
-
2017
- 2017-05-01 US US15/583,317 patent/US20170231927A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2015107517A (ru) | 2016-10-10 |
| IN2015DN01023A (enExample) | 2015-06-26 |
| WO2014028878A1 (en) | 2014-02-20 |
| AU2013302359A1 (en) | 2015-03-19 |
| US20170231927A1 (en) | 2017-08-17 |
| EP2884967B1 (en) | 2017-02-01 |
| CN104755074A (zh) | 2015-07-01 |
| US20140050784A1 (en) | 2014-02-20 |
| IL237139A0 (en) | 2015-04-30 |
| MX2015001917A (es) | 2015-10-29 |
| EP2884967A1 (en) | 2015-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2428064T3 (es) | Sistemas de liberación pulsátil controlada | |
| ES2298551T3 (es) | Formulacion farmaceutica oral en forma de una pluralidad de microcapsulas que permiten la liberacion prolongada de principio(s) activo(s) poco soluble(s). | |
| JP5808670B2 (ja) | 弱塩基性薬物を含む組成物及び徐放性剤形 | |
| ES2226886T3 (es) | Forma de administracion de accion retardada que contiene sacarinato de tramadol. | |
| JP6561105B2 (ja) | 過活動膀胱の治療のための医薬製剤 | |
| ES2590479T3 (es) | Sistemas de administración de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos | |
| RU2428176C2 (ru) | Системы доставки лекарственного средства, содержащие слабоосновные лекарственные средства и органические кислоты | |
| ES2895918T3 (es) | Composiciones farmacéuticas orales de dabigatrán etexilato | |
| ES2582453T3 (es) | Forma farmacéutica oral sólida contra el uso indebido y dotada de un perfil específico de liberación modificada | |
| ES2225183T3 (es) | Formas farmaceuticas de liberacion controlada. | |
| ES2359375T3 (es) | Formas de dosificación de dosis única diaria de trospio. | |
| ES2247320T3 (es) | Medicamento a base de tramadol. | |
| ES2560052T5 (es) | Comprimido bicapa que comprende clorhidrato de benazepril y pimobendan | |
| ES3061097T3 (en) | Lacosamide pharmaceutical composition and pharmaceutical preparation thereof | |
| RS54699B1 (sr) | Višečestične formulacije pantoprazola | |
| US10213389B2 (en) | Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride | |
| MX2010011409A (es) | Forma oral solida con perfil de liberacion dual que contiene particulas multiples. | |
| ES2417330T3 (es) | Minicomprimidos farmacéuticos para la liberación sostenida de acetato de flecainida | |
| EP2994112A1 (en) | Modified release pharmaceutical compositions of dexmethylphenidate or salts thereof | |
| AU2006235483B2 (en) | Controlled release compositions comprising a cephalosporin for the treatment of a bacterial infection | |
| WO2007029087A2 (en) | Controlled release multiple unit formulations | |
| ES2860694T3 (es) | Composición farmacéutica de liberación sostenida que contiene rivastigmina | |
| WO2008079102A1 (en) | Modified release loxoprofen compositions | |
| US9498441B2 (en) | Nitazoxadine composition and process to prepare same | |
| US20090297602A1 (en) | Modified Release Loxoprofen Compositions |